XNAS
ENTA
Market cap351mUSD
Oct 08, Last price
12.10USD
1D
-2.18%
1Q
-11.68%
Jan 2017
-63.88%
IPO
-28.02%
Name
Enanta Pharmaceuticals Inc
Chart & performance
P/E
—
P/S
5.39
EPS
—
Div yield, %
—
Shrs. gr., 5y
1.36%
Rev. gr., 5y
-11.81%
Revenues
65m
-3.42%
Net income
-82m
L-29.43%
CFO
-19m
L-75.53%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Enanta Pharmaceuticals, Inc. is a biotechnology firm dedicated to discovering and advancing small molecule therapies designed to combat a range of viral infections and various liver conditions. Its research and development efforts are primarily focused on addressing pathogens such as respiratory syncytial virus (RSV), SARS-CoV-2, human metapneumovirus (hMPV), and the hepatitis B virus (HBV). The company also holds a strategic partnership and licensing agreement with Abbott Laboratories. This collaboration involves the joint identification, development, and market introduction of specific HCV NS3 and NS3/4A protease inhibitor compounds, including known agents like paritaprevir and glecaprevir, which are utilized in the management of chronic hepatitis C virus. Founded in 1995, Enanta Pharmaceuticals, Inc. operates from its principal office located in Watertown, Massachusetts.
Key people
Paul J. Mellett
Chief Financial Officer, Senior Vice President - Finance & Administration · since 2003
Nathalie Adda
Senior Vice President and Chief Medical Officer · since 2015
Nathaniel S. Gardiner
Senior Vice President, General Counsel · since 2014
Timothy D. Ocain
Senior Vice President - New Product Strategy and Development · since 2014
Yat Sun Or
Senior Vice President - Research & Development, Chief Scientific Officer · since 1999
Stephen Buckley
Independent Director · since 2012
Independent Chairman of the Board · since 2015
Independent Director · since 2014
Independent Director · since 2017
Lesley Russell
Independent Director · since 2016
Legal address
c/o Corporation Service Company, 251 Little Falls Drive
Wilmington, DE 19808
US
Wilmington, DE 19808
US
Headquarters
500 Arsenal street
Watertown, MA 02472
US
Watertown, MA 02472
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑09 | 2024‑09 | 2023‑09 | 2022‑09 | 2021‑09 | 2020‑09 | 2019‑09 | 2018‑09 | 2017‑09 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||